Ceapro Inc V.CZO

Updated Report from Noble Capital Markets

[Ciao]

Noble has a new report dated today, maintaining the $1.08 USD target price.  

Noble CZO Jan 14 report

[Ciao]

Looks like they were sloppy in putting the report together with a contradiction in rev forecasted (ie. the old rev based on milestone payments summary late in the report vs. income statement table)

[fossi_2002]

Ciao - if the numbers in the latest Noble report are indeed true, then I'm not at all surprised at the pressure on the share price. After that, all figures except for sales will be worse in 2021. Gross profit goes down from 9.3 to 8.9 million, research costs go up from 1.8 to 2.8 million and likewise for Selling General and Ad. from 3.5 to 4.3 million. As a result, net profit is supposed to

[upside80]

After 4 years I have no more time and patience, too many other opportunities out there, GLTA on here, my shares will be up for grabs.

[fossi_2002]

Upside80 - I absolutely understand that. Thank you for participating in this message board and good luck in the future.

[upside80]

Thanks to you all, with the exception of those we all have on mute, I've enjoyed reading the comments here. For anyone looking for other ideas, here are some of my current holdings that I think will be exciting opportunities. (EGT-Eguana Tech, CLOV -Clover Health) DYODD Health, peace and prosperity to you all. 

[oats]

upside, Have you exited your position?

[upside80]

Hey Oats, I have not. I own 80k shares so it's going to take me a bit of time, I'm not planning on hammering the ask. 

[Ciao]

Fossi, no doubt, I believe there was already pressure on the stock in mid September. It's in a fine balance for now with investors looking at rev / earnings from the base business which we know supports R&D and it's impact on progress in the product pipeline. Updates on the product pipeline will be critical to keep investors engaged.  Consider how drug companies move from pre

[stockfy]

The latest presentation is helpful too. To me , the presence in China and the strong demand from China for beta glucan is of huge importance. The rising demand from China is a major growth driver while CWO could become a takeover target for a Chinese company: "Total sales of $4,666,000 for the second quarter of 2020 and $8,939,000 for the first six months of 2020 compared to $3,054,000